Enzolytics Inc. (OTCMKTS:ENZC – Get Rating) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 2,306,400 shares, a drop of 63.3% from the February 28th total of 6,281,400 shares. Based on an average daily trading volume, of 7,651,200 shares, the days-to-cover ratio is presently 0.3 days.
Enzolytics Stock Performance
Shares of ENZC stock remained flat at $0.05 during mid-day trading on Thursday. 1,477,179 shares of the stock were exchanged, compared to its average volume of 4,322,108. Enzolytics has a twelve month low of $0.02 and a twelve month high of $0.10. The company has a fifty day moving average price of $0.05 and a 200 day moving average price of $0.05.
Get Enzolytics alerts:About Enzolytics
(Get Rating)
Enzolytics, Inc is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company's all-human monoclonal antibodies target and neutralize human immunodeficiency virus, and are being employed to produce anti-SARS-CoV-2 monoclonal antibodies for treating COVID-19.
Further Reading
- Get a free copy of the StockNews.com research report on Enzolytics (ENZC)
- Is The Bottom In For RH, Or Is This Just A Stopping Point?
- Dividend King H.B. Fuller Signals Slowing In 2023
- Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
- 3 Companies That Just Started Paying Dividends
- Unifirst Is The Next Cintas And Why It Matters For Investors
Receive News & Ratings for Enzolytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzolytics and related companies with MarketBeat.com's FREE daily email newsletter.